Merck Serono Builds $54M VC Bridge Over Troubled Waters
This article was originally published in The Pink Sheet Daily
Corporate venture fund targets promsing assets that are too young for licensing and M&A deals.
You may also be interested in...
Prexton Therapeutics will be headquartered at the Eclosion incubator facility in Geneva and will advance mGluR compounds for Parkinson’s from the Merck Serono portfolio.
Partnership is first investment under Merck Serono Ventures’ €10 million Israel Bioincubator Program.
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth